The Biotechnology Industry Organization (BIO) on Friday thanked Gov. Mitt Romney for his declared plan to shore up more market penetration and rivalry among energy sources by maintaining the RFS in “The Romney Plan For A Stronger Middle Class: ENERGY INDEPENDENCE,” released on Thursday.
There is a series of upcoming BIO events starting next month including BIO India International Conference September 12 – 13, 2012 Mumbai, India, Livestock Biotech Summit September 19 – 21, 2012 Kansas City, MO BIO Investor Forum October 9 – 10, 2012 San Francisco, CA, Pacific Rim Summit on Industrial Biotechnology and Bioenergy October 10 – 12, 2012 Vancouver, Canada and The BIO Convention in China October 24 – 25, 2012 Shanghai, China.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) continues to move up, retaining its top position in the stock market even after posting a loss for the second quarter ended June 30, 2012. For full year 2012, it currently anticipates revenue in a range of $91-$97 million, higher from earlier guidance of $66-$72 million.
Shares of this company traded up 1.77% during trading yesterday, hitting $8.69. The stock has a 52 week low of $1.23 and a 52 week high of $13.50. The company has a market cap of $1.87 billion. The P/S ratio is 63.07 and P/B ratio 17.28. The beta value is 0.21. ARNA’s RSI amounts to 50.50.
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) has recently surpassed its three-month high on twice the average trading volume, and it seems like it is moving forward.
The company has a market value of $88.93 million. It employs 173 people and over the last 12 months generated revenue of $14.45 million and has a net income of -$108.83 million. The firm’s operating margin is -756.72 percent and net profit margin -753.06 percent. The latest closing price of its shares moved up 76.00% from the 50-day moving average.
Hemispherx BioPharma, Inc (AMEX:HEB) topped its 52-week high on Friday. For this company, a return on equity of -28.92 percent was realized due to its financial situation. Last twelve months earnings per share reached a value of -$0.08. Earnings are projected to move up 25.00 percent for the coming five years. The stock closed at $0.659, up 0.069 points or 11.69% from previous close and at a distance of +61.32% from 20-day simple moving average.
Gilead Sciences, Inc.(NASDAQ:GILD) gapped up and closed higher in the last trading session before a FDA ruling today as many believe the good news could secure its place as the leader of the HIV drug pack for a while.
In the last trading session, the stock’s price moved 19.13% above their 200 day moving average, changing hands as low as $34.45 per share. The stock is currently trading 7.35% up from SMA 50. The worst hit in its 52 week range is $34.45 per share, with $58.84 as the 52 week best price, that compares with a latest closing price of $57.29. The Beta of this stock is 0.44.